Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,084 recruiting studies in this area right now.
By phase
- Not applicable2,111
- Phase 21,115
- Phase 1823
- Phase 1/Phase 2481
- Phase 3348
- Phase 4127
- Phase 2/Phase 379
Top conditions
- Multiple Myeloma332
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease140
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia122
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema50
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center64
- City of Hope Medical Center61
- Mayo Clinic61
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California407
- Texas186
- Maryland149
- Alabama148
- Arizona124
- Florida110
- Massachusetts101
- New York98
- Ohio70
- Minnesota68
Recruiting studies5,084 total
- NCT06817395Recruiting
Thinking and memory in chronic ITP
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
Boston, MassachusettsAges 18 years+ - NCT06817590RecruitingPhase 1
Nucleoside therapy for telomere disorders
This trial tests a nucleoside therapy (dC/dT) for people with telomere biology disorders, which cause premature aging and problems like low blood counts, lung or liver issues. The goal is to see if the treatment can help manage these symptoms.
Boston, MassachusettsAges 1–70 - NCT06817720RecruitingPhase 2
Olverembatinib for newly diagnosed chronic phase CML
This trial tests the drug olverembatinib alone for people with newly diagnosed chronic phase CML who have not had much prior treatment. It aims to see how well the drug works and what side effects it may cause.
Houston, TexasAges 18 years+ - NCT06818266RecruitingPhase 3
Tocilizumab for severe chest crisis in sickle cell disease
This trial tests if the drug tocilizumab can help treat acute chest syndrome, a serious lung complication of sickle cell disease. It is for people with sickle cell disease who are hospitalized and need oxygen or breathing support. The study compares tocilizumab to a placebo to see if it speeds up recovery.
ParisAges 2 years+ - NCT06818838RecruitingPhase 1/Phase 2
Gene therapy for Type 1 Gaucher disease
This study tests a new gene therapy called LY-M001 for adults with Type 1 Gaucher disease. It aims to help the body produce the missing enzyme and reduce symptoms like low blood counts or enlarged organs.
Guangzhou, GuangdongAges 18–60 - NCT06819475Recruiting
Muscle health study for childhood leukemia survivors
This study uses imaging to look at how well the mitochondria (the tiny power plants inside your muscle cells) are working. It compares survivors of childhood leukemia who have low muscle mass to healthy volunteers, to understand muscle health and find ways to help.
Memphis, TennesseeAges 18 years+ - NCT06820268RecruitingPhase 1
XS-04 for blood cancers that returned after treatment
This study tests a new drug, XS-04, for people with certain blood cancers (like B-cell lymphoma, AML, or MDS) that have come back or not responded to standard treatments. The goal is to see if the drug is safe and can help shrink tumors or control the disease.
BeijingAges 18–75 - NCT06820515Recruiting
Blood disorder patient registry for all ages
This study is a registry (a large database) that collects information from people who have or may have a blood disorder. It helps researchers learn more about these conditions and improve care.
Hickory, North CarolinaAges Any age - NCT06821880Recruiting
Tracking infections and quality of life in blood cancer patients
This study uses a smartphone or web app to track infections and quality of life in people with multiple myeloma or chronic lymphocytic leukemia who have a weakened immune system. The goal is to create a better screening tool for infections and understand how the disease and treatment affect daily life.
Innsbruck, TyroliaAges 18 years+ - NCT06822829Recruiting
Study of lymphoma that returned as slow-growing type
This study looks at people whose diffuse large B-cell lymphoma came back as a slower-growing lymphoma. Doctors want to understand how and why this happens, using medical records from diagnosis through follow-up.
Reggio EmiliaAges 18 years+ - NCT06822868RecruitingPhase 1
Study of CT1190B for relapsed or refractory B-cell lymphoma
This trial tests a new treatment called CT1190B for people with B-cell non-Hodgkin lymphoma that has come back or stopped responding to at least two prior therapies. It aims to see if CT1190B can help when other treatments have failed or caused side effects.
Beijing, Beijing MunicipalityAges 18–75 - NCT06822972RecruitingPhase 2
Study of Selinexor Plus Bispecific Antibody for Resistant Myeloma
This study tests the drug selinexor in combination with a bispecific antibody for multiple myeloma that has already been treated with at least 4 prior therapies. The goal is to see if the combination is safe and effective for patients whose disease has returned or hasn’t responded to previous treatments.
Durham, North CarolinaAges 18 years+ - NCT06823219Recruiting
Long-term endurance training for sickle cell disease
This study tests whether a long-term endurance exercise program can improve physical fitness, reduce complications, and enhance quality of life for people with sickle cell disease. It is designed for patients whose condition is stable but who have had at least one pain crisis in the last three years.
CréteilAges 15 years+ - NCT06823960Recruiting
Zanubrutinib for marginal zone lymphoma in Italy
This study checks how well and how safely zanubrutinib worked for people with marginal zone lymphoma who got the drug through a special access program in Italy. The goal is to learn more about the drug's real-world effects and help future patients.
Alessandria, AlessandriaAges 18 years+ - NCT06824168RecruitingPhase 2
Quizartinib maintenance for FLT3-ITD AML in remission
This trial tests two different doses of an oral targeted pill called quizartinib (a FLT3 inhibitor) to keep AML with a FLT3-ITD mutation in remission after initial chemo. If you are in first complete remission and haven't had a transplant, this might be an option to lower the chance of relapse.
Baltimore, MarylandAges 18 years+ - NCT06826118RecruitingPhase 2
Car t-cell therapy for relapsed follicular lymphoma
This trial tests a new car t-cell treatment (axicabtagene ciloleucel) for people with follicular lymphoma that has come back or not responded after at least two prior treatments. It aims to see if this therapy can help control the lymphoma.
Xiamen, FujianAges 18 years+ - NCT06826430RecruitingPhase 1
CAR-T cell therapy for severe lupus-related low platelets
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Beijing, Beijing MunicipalityAges 18–70 - NCT06827860RecruitingPhase 2
Talquetamab shot for elderly with relapsed multiple myeloma
This study tests a new drug called talquetamab, given as a shot under the skin, for older adults with multiple myeloma that has come back or stopped responding to earlier treatments. The goal is to see if it can help control the cancer with fewer side effects.
New York, New YorkAges 70 years+ - NCT06827899RecruitingPhase 2
New combination therapy for older adults with untreated leukemia
This trial tests a three-drug combination (venetoclax, chidamide, and azacitidine) followed by another combination (decitabine plus MAG) for older adults with untreated acute myeloid leukemia (AML) who cannot have standard chemotherapy. It aims to offer a gentler but effective treatment option.
Xiamen, FujianAges 60 years+ - NCT06828796RecruitingPhase 2
Early tacrolimus with half-matched stem cell transplant for blood cancer
This trial tests whether giving tacrolimus early after a half-matched donor stem cell transplant can improve outcomes for patients with blood cancer. The donor must be a family member who shares about half of your HLA markers.
Atlanta, GeorgiaAges 18–80 - NCT06828991RecruitingPhase 2
Mosunetuzumab for older DLBCL patients with residual ctDNA
This trial tests whether adding a targeted immunotherapy drug called mosunetuzumab after standard chemotherapy can help older adults with DLBCL who still have tiny traces of cancer DNA in their blood. If you qualify, the goal is to reduce the chance of the cancer coming back.
Rochester, New YorkAges 70 years+ - NCT06829472RecruitingPhase 3
Comparing melphalan doses before stem cell transplant for AML/MDS
This trial compares two different doses of a chemotherapy drug (melphalan) as part of the conditioning treatment before a stem cell transplant. The goal is to find which dose is safer and more effective for people with AML or MDS.
Shanghai, Shanghai MunicipalityAges 18–55 - NCT06829771RecruitingPhase 1/Phase 2
A new drug combined with standard chemo for large B-cell lymphoma
This trial is testing a new drug called TQB2825 given alongside standard chemotherapy (R-CHOP or GemOx) for people with diffuse large B-cell lymphoma (DLBCL) or a related type called grade 3b follicular lymphoma. The goal is to see if adding this new drug is safe and works better than standard treatment alone.
Bengbu, AnhuiAges 18–80 - NCT06829901Recruiting
Uterine entry technique in laser surgery for twin-to-twin transfusion syndrome
This study looks at how doctors enter the uterus during laser surgery to treat twin-to-twin transfusion syndrome (TTTS), a condition where blood flow between twins is unequal. The goal is to see if a certain entry method leads to better outcomes for the babies.
Houston, TexasAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,084 recruiting hematology studies from the U.S. registry right now, out of 7,742 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.